Alan F Schatzberg

List of Publications by Year
in descending order

158	17,081	25034 57	16183 124
papers	citations	h-index	g-index

168	168	168	18331
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial. American Journal of Psychiatry, 2022, 179, 132-141.	7.2	233
2	A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials. Molecular Psychiatry, 2022, 27, 1286-1299.	7.9	68
3	Identification of potential blood biomarkers associated with suicide in major depressive disorder. Translational Psychiatry, 2022, 12, 159.	4.8	16
4	Understanding the Efficacy and Mechanism of Action of a Dextromethorphan-Bupropion Combination: Where Does It Fit in the NMDA Versus mu-Opioid Story?. American Journal of Psychiatry, 2022, 179, 448-450.	7.2	9
5	Understanding the Clinical Effects and Mechanisms of Action of Neurosteroids. American Journal of Psychiatry, 2021, 178, 221-223.	7.2	14
6	Intrinsic reward circuit connectivity profiles underlying symptom and quality of life outcomes following antidepressant medication: a report from the iSPOT-D trial. Neuropsychopharmacology, 2021, 46, 809-819.	5.4	18
7	Cross-Sectional Associations Among Symptoms of Pain, Irritability, and Depression and How These Symptoms Relate to Social Functioning and Quality of Life. Journal of Clinical Psychiatry, 2021, 82, .	2.2	6
8	Unraveling the opioid actions of S-ketamine and R-ketamine: comment on Bonaventura et al.. Molecular Psychiatry, 2021, 26, 6104-6106.	7.9	7
9	Can Target Engagement Studies Miss Their Targets and Mislead Drug Development?. American Journal of Psychiatry, 2021, 178, 372-374.	7.2	3
10	Comment on â€œUnderstanding the Clinical Effects and Mechanisms of Action of Neurosteroidsâ€: Response to Rubinow et al.. American Journal of Psychiatry, 2021, 178, 573-574.	7.2	0
11	Prevalence, Factor Structure, and Heritability of Avoidant Personality Disorder. Journal of Nervous and Mental Disease, 2021, 209, 764-772.	1.0	2
12	Mechanisms of Action of Ketamine and Esketamine. American Journal of Psychiatry, 2021, 178, 1130-1130.	7.2	8
13	Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Molecular Psychiatry, 2020, 25, 1592-1603.	7.9	235
14	Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression. American Journal of Psychiatry, 2020, 177, 716-726.	7.2	321
15	In Memoriam of George Gardos, MD. Neuropsychopharmacology, 2020, 45, 1080-1080.	5.4	0
16	Multisensory modulation of body ownership in mice. Neuroscience of Consciousness, 2020, 2020, niz019.	2.6	2
17	Cannabis and the Developing Adolescent Brain. Current Treatment Options in Psychiatry, 2020, 7, 144-161.	1.9	20
18	Some Comments on Psychedelic Research. American Journal of Psychiatry, 2020, 177, 368-369.	7.2	10

#	Article	IF	Citations
19	Neural cell adhesion molecule peptide mimetics modulate emotionality: pharmacokinetic and behavioral studies in rats and non-human primates. Neuropsychopharmacology, 2019, 44, 356-363.	5.4	6
20	HPA axis in psychotic major depression and schizophrenia spectrum disorders: Cortisol, clinical symptomatology, and cognition. Schizophrenia Research, 2019, 213, 72-79.	2.0	47
21	Nonlinear relationship between early life stress exposure and subsequent resilience in monkeys. Scientific Reports, 2019, 9, 16232.	3.3	16
22	Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism. Molecular Psychiatry, 2019, 24, 1779-1786.	7.9	100
23	Baseline cortisol and the efficacy of antiglucocorticoid treatment in mood disorders: A meta-analysis. Psychoneuroendocrinology, 2019, 110, 104420.	2.7	25
24	More Thoughts on Intranasal Esketamine: Response to Drevets et al.. American Journal of Psychiatry, 2019, 176, 858-859.	7.2	7
25	A Word to the Wise About Intranasal Esketamine. American Journal of Psychiatry, 2019, 176, 422-424.	7.2	68
26	Rigorous Translational Models Are Key to Studying Ketamineâ€™s Antidepressant Mechanism: Response to Wang and Kaplin. American Journal of Psychiatry, 2019, 176, 412-412.	7.2	1
27	Rigorous Trial Design Is Essential to Understand the Role of Opioid Receptors in Ketamineâ€™s Antidepressant Effect. JAMA Psychiatry, 2019, 76, 657.	11.0	11
28	Genome-wide association study identifies 30 loci associated with bipolar disorder. Nature Genetics, 2019, 51, 793-803.	21.4	1,191
29	Scientific Issues Relevant to Improving the Diagnosis, Risk Assessment, and Treatment of Major Depression. American Journal of Psychiatry, 2019, 176, 342-347.	7.2	15
30	Interpreting Ketamineâ€™s Opioid Receptor Dependent Effect: Response to Sanacora. American Journal of Psychiatry, 2019, 176, 249-250.	7.2	7
31	Target Population, Dose, and Timing Considerations for Understanding Naltrexoneâ€™s Subjective Effect: Response to Amiaz. American Journal of Psychiatry, 2019, 176, 251-252.	7.2	4
32	Splice-Break: exploiting an RNA-seq splice junction algorithm to discover mitochondrial DNA deletion breakpoints and analyses of psychiatric disorders. Nucleic Acids Research, 2019, 47, e59-e59.	14.5	22
33	Prefrontal networks dynamically related to recovery from major depressive disorder: a longitudinal pharmacological fMRI study. Translational Psychiatry, 2019, 9, 64.	4.8	43
34	High-dose spaced theta-burst TMS as a rapid-acting antidepressant in highly refractory depression. Brain, 2018, 141, e18-e18.	7.6	138
35	Corticotropin-releasing factor 1 receptor haplotype and cognitive features of major depression. Translational Psychiatry, 2018, 8, 5.	4.8	14
36	Combined Analysis of Mifepristone for Psychotic Depression: Plasma Levels Associated With Clinical Response. Biological Psychiatry, 2018, 84, 46-54.	1.3	61

#	Article	IF	Citations
37	Antidepressant Outcomes Predicted by Genetic Variation in Corticotropin-Releasing Hormone Binding Protein. American Journal of Psychiatry, 2018, 175, 251-261.	7.2	39
38	Empirical evidence of the effect of personality pathology on the outcome of panic disorder. Journal of Psychiatric Research, 2018, 107, 42-47.	3.1	5
39	Diagnostic differences in verbal learning strategies and verbal memory in patients with mood disorders and psychotic disorders. Psychiatry Research, 2018, 269, 733-739.	3.3	2
40	Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism. American Journal of Psychiatry, 2018, 175, 1205-1215.	7.2	338
41	More Research Needed on the Association Between Genotype and Antidepressant Response: Response to Fabbri et al.. American Journal of Psychiatry, 2018, 175, 576-577.	7.2	3
42	Inference of cell type content from human brain transcriptomic datasets illuminates the effects of age, manner of death, dissection, and psychiatric diagnosis. PLoS ONE, 2018, 13, e0200003.	2.5	65
43	Connective Tissue Growth Factor Is a Novel Prodepressant. Biological Psychiatry, 2018, 84, 555-562.	1.3	12
44	Learning to actively cope with stress in female mice. Psychoneuroendocrinology, 2018, 96, 78-83.	2.7	7
45	The Black Book of Psychotropic Dosing and Monitoring. Psychopharmacology Bulletin, 2018, 48, 64-153.	0.0	1
46	A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry, 2017, 74, 399.	11.0	433
47	Resting-state connectivity biomarkers define neurophysiological subtypes of depression. Nature Medicine, 2017, 23, 28-38.	30.7	1,554
48	Mifepristone Plasma Level and Glucocorticoid Receptor Antagonism Associated With Response in Patients With Psychotic Depression. Journal of Clinical Psychopharmacology, 2017, 37, 505-511.	1.4	35
49	Mitochondrial Complex I Deficiency in Schizophrenia and Bipolar Disorder and Medication Influence. Molecular Neuropsychiatry, 2017, 3, 157-169.	2.9	31
50	Post-mortem molecular profiling of three psychiatric disorders. Genome Medicine, 2017, 9, 72.	8.2	147
51	Stress amplifies sex differences in primate prefrontal profiles of gene expression. Biology of Sex Differences, 2017, 8, 36.	4.1	7
52	Side Effects to Antidepressant Treatment in Patients With Depression and Comorbid Panic Disorder. Journal of Clinical Psychiatry, 2017, 78, 433-440.	2.2	29
53	Striatal dopamine D2/3 receptor regulation by stress inoculation in squirrel monkeys. Neurobiology of Stress, 2016, 3, 68-73.	4.0	7
54	Human amygdala engagement moderated by early life stress exposure is a biobehavioral target for predicting recovery on antidepressants. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 11955-11960.	7.1	50

#	Article	IF	Citations
55	Major depressive disorder. Nature Reviews Disease Primers, 2016, 2, 16065.	30.5	1,171
56	The microRNA network is altered in anterior cingulate cortex of patients with unipolar and bipolar depression. Journal of Psychiatric Research, 2016, 82, 58-67.	3.1	61
57	WHITHER KETAMINE AS AN ANTIDEPRESSANT: PANACEA OR TOXIN?. Depression and Anxiety, 2016, 33, 685-688.	4.1	26
58	Constance E. Lieber, Theodore R. Stanley, and the Enduring Impact of Philanthropy on Psychiatry Research. Biological Psychiatry, 2016, 80, 84-86.	1.3	2
59	Eberhard H Uhlenhuth. Neuropsychopharmacology, 2016, 41, 3127-3127.	5.4	0
60	Developing a clinical translational neuroscience taxonomy for anxiety and mood disorder: protocol for the baseline-follow up Research domain criteria Anxiety and Depression (â€œRADâ€) project. BMC Psychiatry, 2016, 16, 68.	2.6	33
61	Evidence for alterations of the glial syncytial function in major depressive disorder. Journal of Psychiatric Research, 2016, 72, 15-21.	3.1	79
62	Learning to cope with stress modulates anterior cingulate cortex stargazin expression in monkeys and mice. Neurobiology of Learning and Memory, 2016, 131, 95-100.	1.9	7
63	NMDA antagonist treatment of depression. Current Opinion in Neurobiology, 2016, 36, 112-117.	4.2	55
64	Issues encountered in recent attempts to develop novel antidepressant agents. Annals of the New York Academy of Sciences, 2015, 1345, 67-73.	3.8	10
65	Impairment and distress patterns distinguishing the melancholic depression subtype: An iSPOT-D report. Journal of Affective Disorders, 2015, 174, 493-502.	4.1	16
66	The International Study to Predict Optimized Treatment in Depression (iSPOT-D): Outcomes from the acute phase of antidepressant treatment. Journal of Psychiatric Research, 2015, 61, 1-12.	3.1	121
67	Response to Transdermal Selegiline Smoking Cessation Therapy and Markers in the 15q24 Chromosomal Region. Nicotine and Tobacco Research, 2015, 17, 1126-1133.	2.6	17
68	A Cognitiveâ€“Emotional Biomarker for Predicting Remission with Antidepressant Medications: A Report from the iSPOT-D Trial. Neuropsychopharmacology, 2015, 40, 1332-1342.	5.4	101
69	Cognitive and emotional biomarkers of melancholic depression: An iSPOT-D report. Journal of Affective Disorders, 2015, 176, 141-150.	4.1	28
70	ABCB1 Genetic Effects on Antidepressant Outcomes: A Report From the iSPOT-D Trial. American Journal of Psychiatry, 2015, 172, 751-759.	7.2	69
71	Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial. American Journal of Psychiatry, 2015, 172, 743-750.	7.2	138
72	Development of New Psychopharmacological Agents for Depression and Anxiety. Psychiatric Clinics of North America, 2015, 38, 379-393.	1.3	16

#	Article	IF	Citations
73	Fibroblast growth factor 9 is a novel modulator of negative affect. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 11953-11958.	7.1	49
74	Decreased Hypothalamic Functional Connectivity with Subgenual Cortex in Psychotic Major Depression. Neuropsychopharmacology, 2015, 40, 849-860.	5.4	40
75	fMRI Activation During Executive Function Predicts Response to Cognitive Behavioral Therapy in Older, Depressed Adults. American Journal of Geriatric Psychiatry, 2015, 23, 13-22.	1.2	66
76	Anna-Monika Award Lecture, DGPPN Kongress, 2013: The role of the hypothalamicâ€“pituitaryâ€“adrenal (HPA) axis in the pathogenesis of psychotic major depression. World Journal of Biological Psychiatry, 2015, 16, 2-11.	2.6	44
77	Neurobiological Signatures of Anxiety and Depression in Resting-State Functional Magnetic Resonance Imaging. Biological Psychiatry, 2015, 77, 385-393.	1.3	130
78	Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders?. Neuropsychopharmacology, 2015, 40, 259-267.	5.4	132
79	Mitochondrial Mutations in Subjects with Psychiatric Disorders. PLoS ONE, 2015, 10, e0127280.	2.5	39
80	Altered choroid plexus gene expression in major depressive disorder. Frontiers in Human Neuroscience, 2014, 8, 238.	2.0	40
81	A Word to the Wise About Ketamine. American Journal of Psychiatry, 2014, 171, 262-264.	7.2	82
82	Coping and glucocorticoid receptor regulation by stress inoculation. Psychoneuroendocrinology, 2014, 49, 272-279.	2.7	23
83	Plasma oxytocin concentrations are lower in depressed vs. healthy control women and are independent of cortisol. Journal of Psychiatric Research, 2014, 51, 30-36.	3.1	79
84	Circadian patterns of gene expression in the human brain and disruption in major depressive disorder. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 9950-9955.	7.1	477
85	The mineralocorticoid receptor agonist, fludrocortisone, differentially inhibits pituitaryâ€“adrenal activity in humans with psychotic major depression. Psychoneuroendocrinology, 2013, 38, 115-121.	2.7	45
86	Altered brain function underlying verbal memory encoding and retrieval in psychotic major depression. Psychiatry Research - Neuroimaging, 2013, 211, 119-126.	1.8	30
87	G protein-linked signaling pathways in bipolar and major depressive disorders. Frontiers in Genetics, 2013, 4, 297.	2.3	67
88	Gene Expression Changes in the Prefrontal Cortex, Anterior Cingulate Cortex and Nucleus Accumbens of Mood Disorders Subjects That Committed Suicide. PLoS ONE, 2012, 7, e35367.	2.5	77
89	Aberrant Brain Activation During a Working Memory Task in Psychotic Major Depression. American Journal of Psychiatry, 2011, 168, 173-182.	7.2	75
90	Efficacy and Safety of Agomelatine in the Treatment of Major Depressive Disorder. Journal of Clinical Psychopharmacology, 2010, 30, 135-144.	1.4	98

#	Article	IF	Citations
91	A pilot study of the phase angle between cortisol and melatonin in major depression â€“ A potential biomarker?. Journal of Psychiatric Research, 2010, 44, 69-74.	3.1	56
92	FKBP5 polymorphisms and antidepressant response in geriatric depression. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 554-560.	1.7	50
93	The silver lining of recent effectiveness trials. World Psychiatry, 2009, 8, 30-32.	10.4	0
94	Response to the Presidential Address. American Journal of Psychiatry, 2009, 166, 1105-1107.	7.2	0
95	Effects of major depression diagnosis and cortisol levels on indices of neurocognitive function. Psychoneuroendocrinology, 2009, 34, 1012-1018.	2.7	50
96	Withdrawal symptoms over time among adolescents in a smoking cessation intervention: Do symptoms vary by level of nicotine dependence?. Addictive Behaviors, 2009, 34, 1017-1022.	3.0	36
97	Glucocorticoid antagonists in neuropsychotic disorders. European Journal of Pharmacology, 2008, 583, 358-364.	3.5	55
98	Achieving Remission and Favorable Outcomes in Patients with Depression/Anxiety and Substance use Disorders. CNS Spectrums, 2008, 13, 10-12.	1.2	3
99	The Acute and Post-Discontinuation Effects of a Glucocorticoid Receptor (GR) Antagonist Probe on Sleep and the HPA Axis in Chronic Insomnia: A Pilot Study. Journal of Clinical Sleep Medicine, 2008, 04, 235-241.	2.6	18
100	Bridging the clinical gap: managing patients with co-occurring mood, anxiety, and alcohol use disorders. Introduction. CNS Spectrums, 2008, 13, 3.	1.2	2
101	Current Issues in the Classification of Psychotic Major Depression. Schizophrenia Bulletin, 2007, 33, 877-885.	4.3	93
102	Resting-State Functional Connectivity in Major Depression: Abnormally Increased Contributions from Subgenual Cingulate Cortex and Thalamus. Biological Psychiatry, 2007, 62, 429-437.	1.3	1,979
103	Safety and tolerability of antidepressants: weighing the impact on treatment decisions. Journal of Clinical Psychiatry, 2007, 68 Suppl 8, 26-34.	2.2	8
104	A Double-Blind, Placebo-Controlled Study of Venlafaxine and Fluoxetine in Geriatric Outpatients With Major Depression. American Journal of Geriatric Psychiatry, 2006, 14, 361-370.	1.2	116
105	Cortisol Circadian Rhythm Alterations in Psychotic Major Depression. Biological Psychiatry, 2006, 60, 275-281.	1.3	180
106	The Neuropsychological Profile of Psychotic Major Depression and its Relation to Cortisol. Biological Psychiatry, 2006, 60, 472-478.	1.3	110
107	New Paradigm for Treating Recurrent Depression: From Symptom Control to Managing Enduring Vulnerabilities. CNS Spectrums, 2006, 11, 22-27.	1.2	5
108	Detecting psychotic major depression using psychiatric rating scales. Journal of Psychiatric Research, 2006, 40, 22-29.	3.1	29

#	Article	IF	Citations
109	Clinical and Biological Effects of Mifepristone Treatment for Psychotic Depression. Neuropsychopharmacology, 2006, 31, 628-636.	5.4	198
110	Reply: Clinical and Biological Effects of Mifepristone Treatment for Psychotic Treatment. Neuropsychopharmacology, 2006, 31, 2795-2797.	5.4	7
111	Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. Journal of Clinical Psychiatry, 2006, 67 Suppl 4, 27-30.	2.2	18
112	Chronic Depression. Archives of General Psychiatry, 2005, 62, 513.	12.3	139
113	Neuropsychological correlates of psychotic features in major depressive disorders: a review and meta-analysis. Journal of Psychiatric Research, 2004, 38, 27-35.	3.1	91
114	A Double-Blind, Randomized Study of Olanzapine and Olanzapine/Fluoxetine Combination for Major Depression With Psychotic Features. Journal of Clinical Psychopharmacology, 2004, 24, 365-373.	1.4	128
115	Randomized Clinical Trial of the Efficacy of Bupropion Combined With Nicotine Patch in the Treatment of Adolescent Smokers.. Journal of Consulting and Clinical Psychology, 2004, 72, 729-735.	2.0	126
116	Pharmacologic treatments of major depression: are two mechanisms really better than one?. Journal of Clinical Psychiatry, 2004, 65 Suppl 4, 3-4.	2.2	0
117	The relationship of chronic pain and depression. Journal of Clinical Psychiatry, 2004, 65 Suppl 12, 3-4.	2.2	8
118	Employing pharmacologic treatment of bipolar disorder to greatest effect. Journal of Clinical Psychiatry, 2004, 65 Suppl 15, 15-20.	2.2	4
119	New approaches to managing psychotic depression. Journal of Clinical Psychiatry, 2003, 64 Suppl 1, 19-23.	2.2	18
120	Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder. Journal of Clinical Psychiatry, 2003, 64 Suppl 13, 30-7.	2.2	6
121	Introduction: treating depression and anxiety to remission. Journal of Clinical Psychiatry, 2003, 64 Suppl 15, 3-4.	2.2	1
122	Prevalence of Depressive Episodes With Psychotic Features in the General Population. American Journal of Psychiatry, 2002, 159, 1855-1861.	7.2	230
123	Double-blind Switch Study of Imipramine or Sertraline Treatment of Antidepressant-Resistant Chronic Depression. Archives of General Psychiatry, 2002, 59, 233.	12.3	123
124	An open label trial of C-1073 (mifepristone) for psychotic major depression*. Biological Psychiatry, 2002, 52, 386-392.	1.3	302
125	Mesotelencephalic dopamine neurochemical responses to glucocorticoid administration and adrenalectomy in Fischer 344 and Lewis rats. Brain Research, 2002, 958, 414-422.	2.2	36
126	Pharmacological principles of antidepressant efficacy. Human Psychopharmacology, 2002, 17, S17-S22.	1.5	32

#	Article	IF	Citations
127	Slowing the progression of cognitive decline in alzheimerâ€™s disease using mifepristone. Journal of Molecular Neuroscience, 2002, 19, 201-206.	2.3	60
128	Clinical use of nefazodone in major depression: a 6-year perspective. Journal of Clinical Psychiatry, 2002, 63 Suppl 1, 18-31.	2.2	1
129	Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. American Journal of Geriatric Psychiatry, 2002, 10, 541-50.	1.2	38
130	Rapid Detection of the Câˆ'1496G Polymorphism in the CYP2D6 *2 Allele. Clinical Chemistry, 2001, 47, 2153-2155.	3.2	6
131	Rapid Reversal of Psychotic Depression Using Mifepristone. Journal of Clinical Psychopharmacology, 2001, 21, 516-521.	1.4	256
132	Sertraline versus imipramine to prevent relapse in chronic depression. Journal of Affective Disorders, 2001, 65, 27-36.	4.1	58
133	Corticosteroids and cognition. Journal of Psychiatric Research, 2001, 35, 127-145.	3.1	247
134	Cortisol Activity and Cognitive Changes in Psychotic Major Depression. American Journal of Psychiatry, 2001, 158, 1612-1616.	7.2	154
135	Successful Long-Term Treatment of Refractory Cushingâ€™s Disease with High-Dose Mifepristone (RU) Tj ETQq1 1 0.784314 rgBT /Ov	3.6	167
136	Dilative cardiomyopathy leading to congestive heart failure in a male squirrel monkey (Saimiri) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 382	0.6	21
137	Glucocorticoid and mineralocorticoid receptor mRNA expression in squirrel monkey brain. Journal of Psychiatric Research, 2000, 34, 383-392.	3.1	216
138	24-Hour Monitoring of Cortisol and Corticotropin Secretion in Psychotic and Nonpsychotic Major Depression. Archives of General Psychiatry, 2000, 57, 755.	12.3	187
139	Neuropsychological Deficits in Psychotic Versus Nonpsychotic Major Depression and No Mental Illness. American Journal of Psychiatry, 2000, 157, 1095-1100.	7.2	192
140	A Comparison of Nefazodone, the Cognitive Behavioral-Analysis System of Psychotherapy, and Their Combination for the Treatment of Chronic Depression. New England Journal of Medicine, 2000, 342, 1462-1470.	27.0	1,188
141	Glucocorticoid Effects on Mesotelencephalic Dopamine Neurotransmission. Neuropsychopharmacology, 1999, 21, 399-407.	5.4	45
142	Hypothalamicâ€“pituitaryâ€“adrenal axis effects on plasma homovanillic acid in man. Biological Psychiatry, 1999, 45, 222-228.	1.3	24
143	Strain differences in mesotelencephalic dopaminergic neuronal regulation between Fischer 344 and Lewis rats. Brain Research, 1999, 832, 152-158.	2.2	19
144	Postnatal foraging demands alter adrenocortical activity and psychosocial development. Developmental Psychobiology, 1998, 32, 285-291.	1.6	84

#	Article	IF	Citations
145	Acute and delayed effects of adrenocorticotropic hormone on dopamine activity in man. Depression, 1994, 2, 292-296.	0.6	2
146	Acute and delayed effects of corticotropin-releasing hormone on dopamine activity in man. Biological Psychiatry, 1994, 36, 616-621.	1.3	22
147	Clozapine response and plasma catecholamines and their metabolites. Psychiatry Research, 1993, 46, 139-149.	3.3	75
148	Relationships between brain ct scan findings and cortisol in psychotic and nonpsychotic depressed patients. Biological Psychiatry, 1989, 26, 565-575.	1.3	91
149	The Roles of Glucocorticoid and Dopaminergic Systems in Delusional (Psychotic) Depression. Annals of the New York Academy of Sciences, 1988, 537, 462-471.	3.8	40
150	Psychotic and nonpsychotic depressions: I. comparisons of plasma catecholamines and cortisol measures. Psychiatry Research, 1987, 20, 143-153.	3.3	56
151	Toward a Biochemical Classification of Depressive Disorders IX. British Journal of Psychiatry, 1985, 146, 633-637.	2.8	15
152	The effects of a single acute dose of dexamethasone on monoamine and metabolite levels in rat brain. Life Sciences, 1985, 36, 2491-2501.	4.3	100
153	A corticosteroid/dopamine hypothesis for psychotic depression and related states. Journal of Psychiatric Research, 1985, 19, 57-64.	3.1	232
154	Dexamethasone increases plasma free dopamine in man. Journal of Psychiatric Research, 1984, 18, 217-223.	3.1	68
155	Commentary 6. Pharmacotherapy, 1984, 4, 324-324.	2.6	0
156	The Hypothalamic-Pituitary-Adrenal Axis in Alcoholics. Alcoholism: Clinical and Experimental Research, 1983, 7, 35-41.	2.4	11
157	The Dexamethasone Suppression Test as a Discriminator among Subtypes of Psychotic Patients. British Journal of Psychiatry, 1982, 141, 471-474.	2.8	72
158	Neurobiologic Foundations of Mood Disorders. , 0, , 339-353.		0